Newron Pharmaceuticals SpA 2023 AR2
The report highlights Newron Pharmaceuticals' clinical and corporate achievements in 2023, particularly the compelling efficacy and safety results of evenamide as an add-on therapy for treatment-resistant schizophrenia. The company also resolved US patent litigation regarding safinamide, securing market exclusivity until at least December 2027. Financially, Newron reported a net loss of EUR 16.2 million, with R&D expenses rising to EUR 13.2 million and Xadago revenues increasing to EUR 9.0 million. On the ESG front, the company published its 2023 ESG Report in compliance with SIX Exchange Regulation directives, highlighting its commitment to diversity, employee training, and carbon offsetting.
Company: Newron Pharmaceuticals SpA
Sector: Health Care
Country: Italy
Year: 2023
Type: AR2
Pages: 100
Newron Pharmaceuticals SpA
Annual Report
The report highlights Newron Pharmaceuticals' clinical and corporate achievements in 2023, particularly the compelling efficacy and safety results of evenamide as an add-on therapy for treatment-resistant schizophrenia. The company also resolved US patent litigation regarding safinamide, securing market exclusivity until at least December 2027. Financially, Newron reported a net loss of EUR 16.2 million, with R&D expenses rising to EUR 13.2 million and Xadago revenues increasing to EUR 9.0 million. On the ESG front, the company published its 2023 ESG Report in compliance with SIX Exchange Regulation directives, highlighting its commitment to diversity, employee training, and carbon offsetting.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Workplace Fatalities
Employees